DK1133285T3 - Fremgangsmåde til fremstilling af partikler hvor en amorf og/eller metastabil krystallinsk region omdannes til krystallinsk tilstand - Google Patents

Fremgangsmåde til fremstilling af partikler hvor en amorf og/eller metastabil krystallinsk region omdannes til krystallinsk tilstand

Info

Publication number
DK1133285T3
DK1133285T3 DK99963731T DK99963731T DK1133285T3 DK 1133285 T3 DK1133285 T3 DK 1133285T3 DK 99963731 T DK99963731 T DK 99963731T DK 99963731 T DK99963731 T DK 99963731T DK 1133285 T3 DK1133285 T3 DK 1133285T3
Authority
DK
Denmark
Prior art keywords
amorphous
converted
particles
crystalline
producing particles
Prior art date
Application number
DK99963731T
Other languages
Danish (da)
English (en)
Inventor
Mikael Bisrat
Saeed Moshashee
Hakan Nyqvist
Mustafa Demirbueker
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of DK1133285T3 publication Critical patent/DK1133285T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Oxygen, Ozone, And Oxides In General (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Recrystallisation Techniques (AREA)
  • Saccharide Compounds (AREA)
DK99963731T 1998-11-23 1999-11-22 Fremgangsmåde til fremstilling af partikler hvor en amorf og/eller metastabil krystallinsk region omdannes til krystallinsk tilstand DK1133285T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9804000A SE9804000D0 (sv) 1998-11-23 1998-11-23 New composition of matter

Publications (1)

Publication Number Publication Date
DK1133285T3 true DK1133285T3 (da) 2006-06-06

Family

ID=20413377

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99963731T DK1133285T3 (da) 1998-11-23 1999-11-22 Fremgangsmåde til fremstilling af partikler hvor en amorf og/eller metastabil krystallinsk region omdannes til krystallinsk tilstand

Country Status (27)

Country Link
US (1) US6475524B1 (sk)
EP (1) EP1133285B1 (sk)
JP (1) JP4447169B2 (sk)
KR (1) KR100697780B1 (sk)
CN (1) CN1198592C (sk)
AT (1) ATE318583T1 (sk)
AU (1) AU767313B2 (sk)
BR (1) BR9915592A (sk)
CA (1) CA2349633C (sk)
CY (1) CY1105609T1 (sk)
CZ (1) CZ20011778A3 (sk)
DE (1) DE69930158T2 (sk)
DK (1) DK1133285T3 (sk)
EE (1) EE200100275A (sk)
ES (1) ES2258865T3 (sk)
HU (1) HUP0104182A2 (sk)
IL (2) IL143040A0 (sk)
IS (1) IS5946A (sk)
NO (1) NO20012514L (sk)
NZ (1) NZ511494A (sk)
PL (1) PL348523A1 (sk)
PT (1) PT1133285E (sk)
SE (1) SE9804000D0 (sk)
SK (1) SK7032001A3 (sk)
TR (1) TR200101424T2 (sk)
WO (1) WO2000030614A1 (sk)
ZA (1) ZA200103946B (sk)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0016002D0 (en) * 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
DE10062712A1 (de) * 2000-12-15 2002-06-20 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und Corticosteroiden
US20040052854A1 (en) * 2000-12-26 2004-03-18 Tomohiro Yoshinari Porous substances and methods for producing the same
EP1401563B2 (en) * 2001-07-02 2015-09-16 Micro & Nano Materials SAGL Process for the production of micro and/or nano particles
GB0126716D0 (en) * 2001-11-07 2002-01-02 Advanced Phytonics Ltd Method for the production of particles
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
RU2006132043A (ru) * 2004-02-06 2008-03-20 МЕДА Фарма ГмбХ унд Ко.КГ (DE) Комбинация и фармацевтический препарат для лечения ринита
TWI341836B (en) 2004-03-11 2011-05-11 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
US8134010B2 (en) 2004-05-05 2012-03-13 Renopharm Ltd. Thiazole-based nitric oxide donors having aryl substituent(s) and uses thereof
WO2005105765A1 (en) 2004-05-05 2005-11-10 Renopharm Ltd. Nitric oxide donors and uses thereof
US7498445B2 (en) 2004-05-05 2009-03-03 Renopharm Ltd. Thiazole-based nitric oxide donors capable of releasing two or more nitric oxide molecules and uses thereof
US7968575B2 (en) 2004-05-05 2011-06-28 Renopharm Ltd. Nitric oxide donors and uses thereof
EP1833822A2 (en) 2004-08-16 2007-09-19 Theravance, Inc. Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
JP5000095B2 (ja) * 2005-03-11 2012-08-15 花王株式会社 有機結晶粒子の製造方法
EP1904219A4 (en) 2005-07-15 2011-07-27 Map Pharmaceuticals Inc METHOD FOR FORMING PARTICLES
DE102006030166A1 (de) * 2006-06-29 2008-01-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tempern
WO2009047935A1 (ja) * 2007-10-12 2009-04-16 Ono Pharmaceutical Co., Ltd. 微粒子
JP2011507676A (ja) * 2007-12-07 2011-03-10 エクスプレイ ミクロパーティクルズ アクティエボラーグ 粒子を生成する方法と構造
JP5138670B2 (ja) * 2009-01-30 2013-02-06 三洋化成工業株式会社 樹脂粒子およびその製造方法
CN102405044A (zh) 2009-02-06 2012-04-04 南加利福尼亚大学 含有单萜的治疗组合物
CA2765621C (en) 2009-07-15 2018-02-13 Theravance, Inc. Crystalline freebase forms of a biphenyl compound
BR112012022209A2 (pt) 2010-03-03 2017-06-06 Neonc Tech Inc composições farmacêuticas compreendendo monoterpenos
US20160038600A1 (en) 2012-08-03 2016-02-11 Neonc Technologies Inc. Pharmaceutical compositions comprising poh derivatives
ES2610425T3 (es) 2010-08-27 2017-04-27 Neonc Technologies Inc. Composiciones farmacéuticas que comprenden carbamatos de alcohol perilílico
CN105616391B (zh) 2010-12-17 2021-03-19 尼昂克技术公司 使用异紫苏醇的方法和装置
WO2014140648A1 (en) 2013-03-15 2014-09-18 Verona Pharma Plc Drug combination
GB201402556D0 (en) 2014-02-13 2014-04-02 Crystec Ltd Improvements relating to inhalable particles
SI3231444T1 (sl) 2014-05-12 2020-04-30 Verona Pharma Plc Novo zdravljenje
WO2016130800A2 (en) 2015-02-12 2016-08-18 Neonc Technologies Inc. Pharmaceutical compositions comprising perillyl alcohol derivatives
JP7144411B2 (ja) 2016-11-30 2022-09-29 ネオンク テクノロジーズ インク． ペリリルアルコール－３－ブロモピルベート複合体及びがんの治療方法
JP7325425B2 (ja) 2018-02-08 2023-08-14 ネオンク テクノロジーズ インク． 血液脳関門を透過性にする方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9101090D0 (sv) 1991-04-11 1991-04-11 Astra Ab Process for conditioning of water-soluble substances
SE9302777D0 (sv) * 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
US5639441A (en) 1992-03-06 1997-06-17 Board Of Regents Of University Of Colorado Methods for fine particle formation
GB9313642D0 (en) 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
GB9413202D0 (en) * 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
WO1996029998A1 (en) 1995-03-28 1996-10-03 Fidia Advanced Biopolymers S.R.L. Nanospheres comprising a biocompatible polysaccharide
EP0969816B1 (en) 1997-03-20 2004-12-15 Schering Corporation Preparation of powder agglomerates

Also Published As

Publication number Publication date
DE69930158T2 (de) 2006-11-16
DE69930158D1 (de) 2006-04-27
CZ20011778A3 (cs) 2001-08-15
SE9804000D0 (sv) 1998-11-23
CN1198592C (zh) 2005-04-27
JP2002530319A (ja) 2002-09-17
CY1105609T1 (el) 2010-07-28
HUP0104182A2 (hu) 2002-03-28
EP1133285A1 (en) 2001-09-19
IS5946A (is) 2001-05-18
TR200101424T2 (tr) 2001-12-21
AU2010400A (en) 2000-06-13
WO2000030614A1 (en) 2000-06-02
ATE318583T1 (de) 2006-03-15
CN1328447A (zh) 2001-12-26
BR9915592A (pt) 2001-08-07
SK7032001A3 (en) 2001-11-06
KR20010080534A (ko) 2001-08-22
NO20012514L (no) 2001-07-19
CA2349633C (en) 2009-06-02
PL348523A1 (en) 2002-06-03
PT1133285E (pt) 2006-06-30
EP1133285B1 (en) 2006-03-01
NO20012514D0 (no) 2001-05-22
US6475524B1 (en) 2002-11-05
IL143040A0 (en) 2002-04-21
NZ511494A (en) 2003-11-28
KR100697780B1 (ko) 2007-03-21
CA2349633A1 (en) 2000-06-02
AU767313B2 (en) 2003-11-06
ES2258865T3 (es) 2006-09-01
EE200100275A (et) 2002-10-15
IL143040A (en) 2009-09-01
ZA200103946B (en) 2002-10-30
JP4447169B2 (ja) 2010-04-07

Similar Documents

Publication Publication Date Title
DK1133285T3 (da) Fremgangsmåde til fremstilling af partikler hvor en amorf og/eller metastabil krystallinsk region omdannes til krystallinsk tilstand
DK1133284T4 (da) Fremgangsmåde til fremstilling af krystallinske partikler
DE60018881D1 (de) Extrakte von mutterkraut (tanacetum parthenium) gegen entzündliche erkrankungen
UY26025A1 (es) Procedimiento para la preparacion de composiciones de celecoxib
FR2627696B1 (fr) Nouvelle forme galenique du fenofibrate
EA200100870A1 (ru) Композиции-ингибиторы циклооксигеназы-2 с быстро наступающим терапевтическим действием
MX9702125A (es) Composiciones y metodos para tratar condiciones inflamatorias mediadas por mastocitos.
RU99128072A (ru) Новая форма s-омепразола
BRPI0314377B8 (pt) composto, composição farmacêutica, tablete ou cápsula, uso de uma quantidade terapeuticamente eficaz, e, processo para preparar um composto
HUP0202461A2 (hu) Gyógyászati készítmények és azok agyvérzés, diabetes és/vagy elzáródásos szívbénulás megelőzésében történő alkalmazása
NO20041994L (no) Nye beta-fenyl-alfa-oksysubstituerte propion derivater: Fremgangsmate for deres fremstilling og deres anvendelse ved fremstilling av farmasoytisk riktige forbindelser
RU93058379A (ru) Фармацевтическая композиция, содержащая определенную липидную систему, способ получения композиции и ее применение
NO176437C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive 2-aminotetralinderivater
GEP20022636B (en) 4-[5-Methyl-3-Phenylisoxazol-4-Yl] Benzenesulfonamide, Its Crystal Structure B, Pharmaceutical Composition Containing The Same, Methods For Treatment Or Prophylaxis Of Disorders Caused By Cyclooxygen-2
HUP0302333A2 (hu) Glatiramer-acetát (kopolimer 1) alkalmazása központi idegrendszeri rendellenességek kezelésére szolgáló gyógyszerkészítmények előállítására
WO2001001974A3 (en) Naaladase inhibitors in anxiety and memory disorders
NO962752L (no) Anvendelse av 2,3-diaryl-1-benzopyranderivater ved fremstilling av et medikament for behandling og forebyggelse av benvevstap og osteoporose
WO2002060435A8 (fr) Cryptotanshinone permettant de prevenir et d'attenuer la maladie d'alzheimer
ATE309811T1 (de) Analgetikum aus schlangengift
NO903384D0 (no) Fremgangsmaate for fremstilling av 4-(n-substituert amino)-2-butynyl-1-urinstoffer og -tiourinstoffer og derivater derav.
NO983860L (no) Nye triazolopuriner, fremgangsmÕte for deres fremstilling og deres anvendelse som legemidler
Bidwell et al. Leg lengthening for short stature in Turner’s syndrome
NO951865L (no) Quinuclidin-derivat som substans-P antagonist
UA40384A (uk) Спосіб лікування хронічного гнійного верхньощелепного синуїту